For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Cohort 1: VIS954 Dose 1 | Participants received a single dose of VIS954 at Dose 1 via SC injection on Day 1. | 0 | None | 0 | 7 | 2 | 7 | View |
| Cohort 2: VIS954 Dose 2 | Participants received a single dose of VIS954 at Dose 2 via SC injection on Day 1. | 0 | None | 0 | 7 | 1 | 7 | View |
| Cohort 3: VIS954 Dose 3 | Participants received a single dose of VIS954 at Dose 3 via SC injection on Day 1. | 0 | None | 0 | 7 | 1 | 7 | View |
| Cohort 4: VIS954 Dose 4 | Participants received a single dose of VIS954 at Dose 4 via SC injection on Day 1. | 0 | None | 0 | 7 | 1 | 7 | View |
| Cohort 5: VIS954 Dose 5 | Participants received a single dose of VIS954 at Dose 5 via SC injection on Day 1. | 0 | None | 0 | 7 | 3 | 7 | View |
| Cohort 6: VIS954 Dose 6 | Participants received a single dose of VIS954 at Dose 6 via SC injection on Day 1. | 0 | None | 0 | 7 | 2 | 7 | View |
| Cohort 1 to 6: Pooled Placebo | Participants received a single dose of placebo matched to VIS954 via SC injection on Day 1. | 0 | None | 0 | 12 | 4 | 12 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Blood loss anaemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | MedDRA (27.0) | View |
| Diarrhoea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (27.0) | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA (27.0) | View |
| Injection site bruising | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (27.0) | View |
| Injection site pruritus | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (27.0) | View |
| Injection site reaction | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (27.0) | View |
| Upper respiratory tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDRA (27.0) | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDRA (27.0) | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (27.0) | View |
| Rhinorrhoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (27.0) | View |